PepGen Inc
PEPG
查看详细走势图
5.343USD
-0.097-1.78%
交易中 （美东）报价延迟15分钟
367.34M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.78%
5天
-2.31%
1月
-3.90%
6月
+268.51%
今年开始到现在
+40.99%
1年
+47.20%
查看详细走势图
TradingKey PepGen Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
PepGen Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
10.000
目标均价
+78.89%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
PepGen Inc亮点
亮点风险
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-1.83，处于3年历史合理位
机构加仓
最新机构持股40.93M股，环比增加2.64%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值1.23K
PepGen Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
PepGen Inc简介
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
公司代码PEPG
公司PepGen Inc
CEOMcArthur (James G)
网址https://pepgen.com
常见问题
PepGen Inc(PEPG)的当前股价是多少？
PepGen Inc(PEPG)的当前股价是 5.343。
PepGen Inc的股票代码是什么？
PepGen Inc的股票代码是PEPG。
PepGen Inc股票的52周最高点是多少？
PepGen Inc股票的52周最高点是6.720。
PepGen Inc股票的52周最低点是多少？
PepGen Inc股票的52周最低点是0.880。
PepGen Inc的市值是多少？
PepGen Inc的市值是367.34M。
PepGen Inc的净利润是多少？
PepGen Inc的净利润为-89.98M。
现在PepGen Inc(PEPG)的股票是买入、持有还是卖出？
根据分析师评级，PepGen Inc(PEPG)的总体评级为买入，目标价格为10.000。
PepGen Inc(PEPG)股票的每股收益（EPS TTM）是多少
PepGen Inc(PEPG)股票的每股收益（EPS TTM）是-2.824。
相关品种
